Clinical Trials · NCT00006269
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Novartis
- Enrollment
- 89
- Start date
- Dec 1999
- Locations
- 2 sites, United States
- Primary endpoint
- Study in Colorectal Cancer